natgillin/translations-raw huggingface dataset:
Vardenafil dose adjustment is necessary if moderate or potent CYP 3A4 inhibitors are given concomitantly (see section 4.5).
Prilagodba doze vardenafila neophodna je ako se istodobno primjenjuju umjereni ili jaki inhibitori CYP3A4, (vidjeti dio 4.5).
Vardenafil dose adjustment is necessary if moderate or potent CYP 3A4 inhibitors are given concomitantly (see section 4.5).
Prilagodba doze vardenafila neophodna je ako se istovremeno primjenjuju umjereni ili jaki inhibitori CYP3A4, (vidjeti dio 4.5).
Vardenafil dose adjustment might be necessary if moderate CYP 3A4 inhibitors such as erythromycin and clarithromycin, are given concomitantly (see section 4.2 and 4.5).
Kada se se istodobno daju umjereni inhibitori CYP3A4, kao što su eritromicin i klaritromicin, može biti neophodno prilagoditi dozu vardenafila (vidjeti dijelove 4.2 i 4.5).
Vardenafil dose adjustment might be necessary if moderate CYP3A4 inhibitors such as erythromycin and clarithromycin, are given concomitantly (see sections 4.5 and 4.2).
Kada se se istodobno daju umjereni inhibitori CYP3A4, kao što su eritromicin i klaritromicin, može biti neophodno prilagoditi dozu vardenafila (vidjeti dijelove 4.5 i 4.2).
Vardenafil in film-coated tablets is metabolised predominantly by hepatic metabolism via cytochrome P450 (CYP) isoform 3A4 with some contribution from CYP3A5 and CYP2C isoforms.
Vardenafil iz filmom obloženih tableta metabolizira se pretežno jetrenim metabolizmom putem izoenzima 3A4 citokroma P450 (CYP) uz manji doprinos izoenzima CYP3A5 i CYP2C.
vardenafil in men older than 75 years – medicine to treat erectile dysfunction in adults men certain medicines for HIV: saquinavir/ritonavir, saquinavir certain medicines to treat long-term (chronic) hepatitis C (an infectious disease that affects the liver, caused by the hepatitis C virus): Paritaprevir/Ombitasvir (ritonavir) methadone: medicine to treat dependence to drugs
vardenafil u muškaraca starijih od 75 godina - lijek za liječenje erektilne disfunkcije u odraslih muškaraca određene lijekove za HIV: sakvinavir/ritonavir, sakvinavir određene lijekove za liječenje dugotrajnog (kroničnog) hepatitisa C (zarazna bolest koja zahvaća jetru, a uzrokuje ju virus hepatitisa C): paritaprevir/ombitasvir (ritonavir) metadon: lijek za liječenje ovisnosti o drogama
vardenafil in men older than 75-years due to increased risk of adverse events
vardenafil u muškaraca starijih od 75 godina zbog povećanog rizika od nuspojava
Vardenafil Increased plasma concentrations of vardenafil (see section 4.4. and 4.5).
Vardenafil Povišena koncentracija vardenafila u plazmi (vidjeti dijelove 4.4 i 4.5).
Vardenafil Increased plasma concentrations of vardenafil (see section 4.4. and 4.5).
Vardenafil Povišena koncentracija vardenafila u plazmi (vidjeti dio 4.4 i 4.5).
Vardenafil Increased plasma concentrations of vardenafil (see sections 4.4 and 4.5)
Vardenafil Povišena koncentracija vardenafila u plazmi (vidjeti dijelove 4.4 i 4.5).
Vardenafil is contraindicated in men older than 75 years old (see section 4.3).
Vardenafil je kontraindiciran u muškaraca starijih od 75 godina (vidjeti dio 4.3).
Vardenafil is rapidly absorbed after administration of 10 mg orodispersible tablets without water.
Vardenafil se brzo apsorbira nakon primjene Vivanza 10 mg raspadljivih tableta za usta bez vode.
Vardenafil is rapidly absorbed after administration of vardenafil 10 mg orodispersible tablets without water.
Vardenafil se brzo apsorbira nakon primjene vardenafil 10 mg raspadljivih tableta za usta bez vode.
Vardenafil may be administered at any time with tamsulosin or with alfuzosin.
Vardenafil se može primjeniti u bilo koje vrijeme s tamsulozinom ili alfuzosinom.
Vardenafil was not found to accumulate in the plasma in patients aged 45 years and below or 65 years or over following once-daily dosing of vardenafil 10 mg orodispersible tablets over ten days.
Nije se pronašlo da se vardenafil nakuplja u plazmi bolesnika u dobi do 45 godina ili u dobi od 65 godina i starijih nakon doziranja Vivanza 10 mg raspadljivih tableta za usta jedanput na dan tijekom deset dana.
Vardenafil:
Flutikazon propionat:
Vardenafil:
Vardenafil
Vardenafil: AUC: ↑ 10-fold Cmax: ↑ 4-fold
Vardenafil: AUC: ↑ 10 puta Cmax: ↑ 4 puta
Vardenafil: AUC: ↑ 49-fold
Vardenafil: AUC: ↑ 49 puta
Varenicline
Vareniklin
Varenicline (N=1130)
Vareniklin (N=1130)
Varenicline binds with high affinity and selectivity at the α4β2 neuronal nicotinic acetylcholine receptors, where it acts as a partial agonist - a compound that has both agonist activity, with lower intrinsic efficacy than nicotine, and antagonist activities in the presence of nicotine.
Vareniklin se s visokim afinitetom i selektivnošću veže za α4β2 neuronske nikotinske acetilkolinske receptore, gdje djeluje kao djelomični agonist - tvar koja djeluje i kao agonist, s manjom intrinzičnom djelotvornošću od nikotina, ali i kao antagonist u prisutnosti nikotina.
Varenicline binds with high affinity and selectivity at the α4β2 neuronal nicotinic acetylcholine receptors, where it acts as a partial agonist - a compound that has both agonist activity, with lower intrinsic efficacy than nicotine, and antagonist activities in the presence of nicotine.
Vareniklin se s visokim afinitetom i selektivnošću veže za α4β2 neuronske nikotinske acetilkolinske receptore, gdje djeluje kao djelomični agonist – tvar koja djeluje i kao agonist, s manjom intrinzičnom djelotvornošću od nikotina, ali i kao antagonist u prisutnosti nikotina.
Varenicline did not alter the steady-state pharmacokinetics of bupropion.
Vareniklin nije izmijenio farmakokinetiku bupropiona u stanju dinamičke ravnoteže.
Varenicline has been shown to be dialyzed in patients with end stage renal disease (see section 5.2), however, there is no experience in dialysis following overdose.
Pokazalo se da se vareniklin može odstraniti dijalizom u bolesnika u terminalnoj fazi bubrežne bolesti (vidjeti dio 5.2), ali nema iskustva s dijalizom nakon predoziranja.
Varenicline is not recommended during pregnancy.
Ne preporučuje se koristiti vareniklin tijekom trudnoće.
Varenicline pharmacokinetics were unchanged in subjects with mild renal impairment (estimated creatinine clearance > 50 ml/min and  80 ml/min).
Farmakokinetika vareniklina ostala je neizmijenjena u ispitanika s blagim oštećenjem bubrežne funkcije (procijenjeni klirens kreatinina > 50 ml/min i ≤ 80 ml/min).
Varenicline vs Placebo
Vareniklin
Varenicline vs Placebo
Vareniklin naspram placeba
Vargatef + Docetaxel
Vargatef + docetaksel
Vargatef 100 mg capsules Nintedanib
Vargatef 100 mg meke kapsule nintedanib
Vargatef 100 mg soft capsules are peach-coloured, opaque, oblong capsules imprinted on one side in black with the Boehringer Ingelheim company symbol and the figure “100”.
Vargatef 100 mg meke kapsule su boje breskve, neprozirne, duguljaste kapsule koje na jednoj strani imaju u crnoj boji utisnute logo tvrtke Boehringer Ingelheim i oznaku „100“.
Vargatef 100 mg soft capsules nintedanib
Vargatef 100 mg meke kapsule nintedanib
Vargatef 100 mg soft capsules Vargatef 150 mg soft capsules
Vargatef 100 mg meke kapsule Vargatef 150 mg meke kapsule
Vargatef 150 mg capsules are brown-coloured, opaque, oblong capsules imprinted on one side in black with the Boehringer Ingelheim company symbol and the figure “150”.
Vargatef 150 mg kapsule su smeđe boje, neprozirne, duguljaste kapsule koje na jednoj strani imaju u crnoj boji utisnute logo tvrtke Boehringer Ingelheim i oznaku „150“.
Vargatef 150 mg capsules Nintedanib
Vargatef 150 mg meke kapsule nintedanib
Vargatef 150 mg soft capsules nintedanib
Vargatef 150 mg meke kapsule nintedanib
Vargatef contains soya
Vargatef sadrži soju
Vargatef has minor influence on the ability to drive and use machines.
Vargatef u manjoj mjeri utječe na sposobnost upravljanja vozilima i rada sa strojevima.
Vargatef is indicated in combination with docetaxel for the treatment of adult patients with locally advanced, metastatic or locally recurrent non-small cell lung cancer (NSCLC) of adenocarcinoma tumour histology after first-line chemotherapy.
Vargatef je indiciran u kombinaciji s docetakselom za liječenje odraslih bolesnika s lokalno uznapredovalim, metastatskim ili lokalno rekurentnim karcinomom pluća ne-malih stanica (NSCLC; engl. non-small cell lung cancer) s histološkim nalazom adenokarcinoma, nakon kemoterapije kao prve linije liječenja.
Vargatef is used to treat a type of non-small cell lung cancer called ‘adenocarcinoma’, when the cancer is locally advanced, metastatic (when cancer cells have spread from the original site to other parts of the body) or locally recurrent (when the cancer has come back in the same area).
„adenokarcinom“, ako je karcinom lokalno uznapredovao, metastazirao (nakon što su se stanice karcinoma proširile s izvornog mjesta u druge dijelove tijela) ili lokalno rekurentan (ako su se stanice karcinom vratile u neke dijelove tijela).
Variability in rivaroxaban pharmacokinetics is moderate with inter-individual variability (CV %) ranging from 30 % to 40 %, apart from on the day of surgery and the following day when variability in exposure is high (70 %).
Varijabilnost farmakokinetike rivaroksabana umjerena je s interindividualnom varijabilnošću (CV %) u rasponu od 30 do 40 %, osim na dan kirurškog zahvata i dan kasnije, kada je varijabilnost u izloženosti lijeku velika (70 %).
Variability in rivaroxaban pharmacokinetics is moderate with inter-individual variability (CV%) ranging from 30% to 40%.
Varijabilnost farmakokinetike rivaroksabana umjerena je s interindividualnom varijabilnošću (CV%) u rasponu od 30% to 40%.
Variable statistic
Statistička
Variable/ statistic Cetuximab plus BSC
varijabla/statistika Cetuksimab i BSC
Variable/ statistic Cetuximab plus FOLFIRI
varijabla/ statistika Cetuksimab i FOLFIRI
Variable/ statistic Cetuximab plus FOLFIRI
varijabla/statistika Cetuksimab i FOLFIRI
Variable/ statistic Cetuximab plus FOLFOX4
varijabla/statistika Cetuksimab i FOLFOX4
Variable/ statistic Cetuximab plus OxMdG
varijabla/statistika Cetuksimab i OxMdG
Variants were selected at NS5A resistance associated positions 24, 28, 30, 31, 32, 58, 92 and 93.
Odabrane su varijante na mjestima povezanim s rezistencijom NS5A 24, 28, 30, 31, 32, 58, 92 i 93.
Varicella (titre
Varičela (titar
Varicella virus3 Oka/Merck strain (live, attenuated) ................... not less than 3.99 log10 PFU**
živi, atenuirani virus varičele3, soj Oka/Merck ........................... ne manje od 3,99 log10 PFU
Varicella virus3 Oka/Merck strain (live, attenuated) ................... not less than 3.99 log10 PFU**
živi, oslabljeni virus varičele3, soj Oka/Merck ........................... ne manje od 3,99 log10 PFU
Varicella-zoster virus Oka/Merck strain, (live, attenuated) ≥19400 PFU
Varicella-zoster virus, soj Oka/Merck (živi, atenuirani) ≥19 400 PFU
Varicella-zoster virus, Oka/Merck strain, (live, attenuated) ≥19400 PFU
Varicella-zoster virus, soj Oka/Merck (živi, atenuirani) ≥19 400 PFU
Varicella-zoster virus1, Oka/Merck strain, (live, attenuated) not less than 19400 PFU (plaque-forming units).
Varicella-zoster virus1, soj Oka/Merck, (živi, oslabljeni) ne manje od 19 400 PFU (jedinice koje stvaraju plak).
Varicella-zoster virus1, Oka/Merck strain, (live, attenuated) not less than 19400 PFU2 1produced in human diploid (MRC-5) cells
virus varicella-zoster1, soj Oka/Merck (živi, atenuirani) ne manje od 19400 PFU2 1umnožen na ljudskim diploidnim (MRC-5) stanicama
varicose veins in the gullet (oesophageal varices)
proširene vene jednjaka (ezofagealni varikoziteti)
Various doses of Volibris (2.5, 5 and 10 mg) have been compared with placebo (a dummy treatment) in two main studies involving a total of 394 patients with PAH, most of whom had class II or III disease that was of unknown cause or caused by connective tissue disease.
Različite doze lijeka Volibris (2,5, 5 i 10 mg) uspoređene su s placebom (slijepo liječenje) u dvama glavnim ispitivanjima koja su uključivala 394 bolesnika s PAH-om, od kojih je većina imala klasu II ili klasu III bolesti čiji uzrok nije bio poznat ili je bila uzrokovane bolešću vezivnog tkiva.
various steroids - such as dexamethasone, ethinyl estradiol, fluticasone
različite steroide, poput deksametazona, etinilestradiola, flutikazona
Various visceral effects (discoloration, red foci at different organs, small colourless mass above atrio- ventricular valve, small gall bladder, malformed diaphragm) were also observed in single foetuses.
U pojedinih fetusa uočeni su također i različiti učinci na unutarnje organe (promjena boje, crvena žarišta na različitim organima, mala bezbojna masa iznad atrioventrikularnog zaliska, mali žučni mjehur, malformirana dijafragma).
Varvara Athens
Varvara Atena
Varvara, Athens, Greece
Varvara, Atena, Grčka
Vary the injection site with each injection.
Svaki puta odaberite drugo mjesto uboda.
Vary the site from day to day.
Svakog dana treba injicirati u drugo mjesto.
Vascular
Krvožilni
Vascular
Krvožilni poremeć aji
Vascular
Krvožilni poremećaji
Vascular
Rijetko
Vascular
Često
Vascular access thrombosis
tromboza krvožilnog pristupa
Vascular adverse reactions
Krvožilne nuspojave
vascular arterial occlusion,
okluzije arterijskih žila,
Vascular Death
Vaskularna smrt
Vascular disorder
Krvožilni poremećaji
Vascular disorder
Poremećaj krvnih žila
Vascular disorders
Endokrini poremećaji
Vascular disorders
gastritis, gastroezofagealna refluksna
Vascular disorders
halucinacije1
Vascular disorders
hipoksija
Vascular disorders
Krvnožilni poremećaji
Vascular disorders
Krvoţilni poremećaji
VASCULAR DISORDERS
KRVOŽILNI POREMEĆAJI
Vascular disorders
Krvožil ni poremeć aji
Vascular disorders
Krvožilni
Vascular disorders
Krvožilni poremeć aji
Vascular disorders
Krvožilni poremećaji:
Vascular disorders
Krvožilni poremećji
Vascular disorders
Krvožilno poremećaji
Vascular disorders
Manje često
Vascular disorders
Opći poremećaji i reakcije na mjestu primjene
Vascular disorders
poremećaji
Vascular disorders
Poremećaji kože i potkožnog tkiva
Vascular disorders
Poremećaji krvi i limfnog sustava
Vascular disorders
Poremećaji krvnih žila
Vascular disorders
Poremećaji krvožilnog sustava
Vascular disorders
Poremećaji metabolizma i prehrane
Vascular disorders
Poremećaji oka
Vascular disorders
Poremećaji probavnog sustava
Vascular disorders
Poremećaji živčanog sustava
Vascular disorders
psihotični poremećaje, deluzijae,
Vascular disorders
Srčani poremećaji
Vascular disorders
sustava
Vascular disorders Common Hypertension, flushing, blood pressure increased
Krvožilni poremećaji često hipertenzija, crvenilo uz osjećaj vrućine, povišen
Vascular disorders Not known: postural hypotension
Krvožilni poremećaji Nije poznato: posturalna hipotenzija
Vascular disorders Rare: hypotension
Krvožilni poremećaji Rijetko: hipotenzija
Vascular disorders Uncommon Hot flush
Krvožilni poremećaji manje često navala vrućine
Vascular disorders Uncommon: flushing
Krvožilni poremećaji Manje često: crvenilo praćeno osjećajem vrućine
Vascular disorders Vasculitis
Krvožilni poremećaji Vaskulitis
Vascular disorders, including veno-occlusive disease and fluid volume disturbances, have been reported occasionally in patients undergoing high dose chemotherapy followed by transplantation.
Krvožilni poremećaji, uključujući venookluzivnu bolest i poremećaje volumena tekućine prijavljeni su povremeno kod bolesnika koji se podvrgavaju visokoj dozi kemoterapije nakon čega slijedi transplantacija.
Vascular disorders4
Krvožilni poremećaji4
Vascular disorders:
Krvožilni poremećaji
Vascular disorders:
Krvožilni poremećaji:
Vascular disorders:
Poremećaji živčanog sustava:
Vascular disorders:
Vaskularni poremećaji:
Vascular disorders: Not known: postural hypotension
Krvožilni poremećaji: Nepoznato: posturalna hipotenzija
Vascular disorders: Uncommon: flushing
Krvožilni poremećaji: Manje često: crvenilo praćeno osjećajem vrućine
Vascular disorders: uncommon: hypertension
Krvožilni poremećaji: manje često: hipertenzija
Vascular Doppler imaging: 2.4 ml.
Snimanje žila dopplerom: 2,4 ml.
Vascular mortality
Vaskularna smrtnost
Vascular occlusion adverse events were more frequent with increasing age and in patients with prior history of ischaemia, hypertension, diabetes, or hyperlipidaemia.
Štetni događaji vaskularne okluzije bivali su češći s porastom godina i u bolesnika s prethodnom anamnezom ishemije, hipertenzije, dijabetesa, ili hiperlipidemije.
vascular retinopathy bronchiectasis or history of pulmonary bleeding
vaskularnom retinopatijom s bronhiektazijama ili anamnezom plućnog krvarenja
Vascular rupture
Puknuće krvne žile.
Vascular rupture: see section 4.3
Ruptura stijenke krvne žile; vidjeti dio 4.3
vasculitides, lupus erythematosus, drug hypersensitivity (including anaphylactic shock), allergic disorders, auto-antibody positive
vaskulitisi, lupus eritematozus, preosjetljivost na lijek (uključujući anafilaktički šok), alergijske reakcije, pozitivna auto-antitijela
vasculitis
Nepoznato
vasculitis (inflammation of blood vessels which can cause skin rashes, joint pain and kidney problems) neurological disorders such as encephalomyelitis (inflammation of the central nervous system), neuritis (inflammation of nerves) and a type of paralysis known as Guillain-Barré Syndrome
vaskulitis (upala krvnih žila koja može uzrokovati kožne osipe, bol u zglobovima i probleme s bubrezima) neurološki poremećaji kao što su encefalomijelitis (upala središnjeg živčanog sustava), neuritis (upala živaca) i vrsta paralize poznata kao Guillain-Barréov sindrom
vasculitis (inflammation of blood vessels)
vaskulitis (upala krvnih žila)
vasculitis (inflammation of blood vessels);
vaskulitis (upala krvnih žila)
Vasculitis (inflammation of the blood vessels which can cause skin rashes, joint pain and kidney problems)
Vaskulitis (upala krvnih žila što može uzrokovati kožne osipe, bol u zglobovima i probleme s bubrezima)
Vasculitis (inflammation of the blood vessels which can cause skin rashes, joint pain and kidney problems), and exudative erythema multiforme (type of allergic skin reaction that occurs in response to medications, infections, or illness).
Vaskulitis (upala krvnih žila koja može prouzročiti kožni osip, bol u zglobovima i probleme s bubrezima) i eksudativni multiformni eritem (vrsta alergijske kožne reakcije koja se pojavljuje kao odgovor na lijekove, infekcije ili bolest).
vasculitis (predominatel y cutaneous), leukocytoclast ic vasculitis
vaskulitis (pretežno kutani), leukocitoklastičn i vaskulitis
Vasculitis with transient renal involvement
Vaskulitis s prolaznim zahvaćanjem bubrega
Vasculitis with transient renal involvement.
Vaskulitis s prolaznim zahvaćanjem bubrega
vasculitis,
Pretrage
vasculitis, angiopathyb, peripheral ischaemia, orthostatic hypotension
vaskulitis, angiopatijab, periferna ishemija, ortostatska hipotenzija
Vasculitis: narrow SMQ “Vasculitis”
Vaskulitis: suženi SMQ “Vaskulitis”
Vasculitis: narrow SMQ “Vasculitis”
Vaskulitis: uski SMQ “Vaskulitis”
Vasculitisam
Vaskulitisam
Vasectomised males should wear a condom if engaged in sexual activity with a pregnant woman or a woman of childbearing potential as seminal fluid may still contain pomalidomide in the absence of spermatozoa.
Muškarci kojima je učinjena vazektomija moraju upotrebljavati prezervative pri spolnoj aktivnosti s trudnicom ili ženom reproduktivne dobi jer sjemena tekućina može sadržavati pomalidomid čak i u odsutnosti spermatozoida.
Vasectomy
Vazektomija
Vaso-occlusive crises in patients with sickle cell anaemia
Vazookluzivne krize u bolesnika s anemijom srpastih stanica
Vasodilatation Flushing
vazodilatacija crvenilo uz osjećaj vrućine
vasodilatation,
vazodilatacija,
Vasodilating agents
boceprevira.
Vasodilating agents
Vazodilatatori
Vasodilation
vazodilatacija
Vasodilation (B), Postural hypotension (B)
vazodilatacija (B), posturalna hipotenzija (B)
Vasodilators (peripheral)
Vazodilatatori (periferni)
vasodilators (used to widen blood vessels resulting from smooth muscle relaxation), or, if you are undergoing radiation therapy,
vazodilatatori (kojima se proširuju krvne žile uslijed opuštanja glatkih mišića), ili, ako primate terapiju zračenjem,
Vasopressin regulates the level of water and sodium in the body.
Vazopresin regulira koncentracije vode i natrija u tijelu.
Vasopression is a hormone that helps prevent the loss of water from the body by reducing urine output.
Vazopresin je hormon koji pomaže spriječiti gubitak vode iz tijela tako što smanjuje izlučivanje urina.
Vasospasm (rare)
(rijetko)
Vasovagal reactions, orthostatic hypotension, and/or syncope can occur following subcutaneous injections (see section 4.8).
Nakon supkutane injekcije mogu se javiti vazovagalne reakcije, ortostatska hipotenzija i/ili sinkopa (vidjeti dio 4.8).
Vasovagal reactions1.
Vazovagalne reakcije1.
vasovagal, loss
gubitak
Vaxelis can be given at the same time as other vaccines such as pneumococcal vaccines, measles- mumps-rubella-varicella (MMRV) vaccines, rotavirus vaccines or meningococcal C vaccines.
Vaxelis se može davati istodobno s drugim cjepivima, kao što su cjepiva protiv pneumokoka, MMRV cjepiva protiv ospica, zaušnjaka, rubele i vodenih kozica, cjepiva protiv rotavirusa ili cjepiva protiv meningokoka grupe C.
Vaxelis does not protect your child against diseases caused by other bacteria and viruses that may cause similar symptoms.
Vaxelis ne štiti Vaše dijete od bolesti uzrokovanih drugim bakterijama i virusima, koje mogu imati slične simptome.
Vaxelis injection IM
Injekcija cjepiva Vaxelis i.m.
Vaxelis is a vaccine, which helps to protect your child against diphtheria, tetanus, pertussis, hepatitis B, poliomyelitis and serious diseases caused by Haemophilus influenzae type b.
Vaxelis je cjepivo koje pomaže u zaštiti Vašeg djeteta protiv difterije, tetanusa, hripavca, hepatitisa B, poliomijelitisa i teških oboljenja prouzročenih bakterijom Haemophilus influenzae tip b.
Vaxelis is given to children from the age of six weeks.
Vaxelis se primjenjuje u djece nakon navršenih šest tjedana starosne dobi.
Vaxelis will not prevent disease caused by pathogens other than Corynebacterium diphtheriae, Clostridium tetani, Bordetella pertussis, hepatitis B virus, poliovirus or Haemophilus influenzae type b.
Vaxelis neće spriječiti bolesti prouzročene patogenima koji nisu bakterija Corynebacterium diphtheriae, bakterija Clostridium tetani, bakterija Bordetella pertussis, virus hepatitisa B, poliovirus ili bakterija Haemophilus influenzae tipa b.
Vaxelis will only help to prevent these diseases caused by the bacteria and viruses targeted by the vaccine.
Vaxelis će pomoći u sprječavanju samo onih bolesti koje uzrokuju bakterije i virusi protiv kojih je ovo cjepivo namijenjeno.
Vaxxitek HVT+IBD Suspension and solvent for suspension for injection
Vaxxitek HVT+IBD suspenzija i razrjeđivač za suspenziju za injekcije.
Vc+Dx+T
Vc+ Dx+T
Vc+M+P n=344
Vc+M+P n = 344
Vc=VELCADE; Dx=dexamethasone; T=thalidomide a Thalidomide dose is increased to 100 mg from week 3 of Cycle 1 only if 50 mg is tolerated and to 200 mg from cycle 2 onwards if 100 mg is tolerated. b Up to 6 cycles may be given to patients who achieve at least a partial response after 4 cycles
Vc = VELCADE; Dx = deksametazon; T = talidomid a Doza talidomida se povisuje na 100 mg od 3. tjedna 1. ciklusa samo ako se podnosi doza od 50 mg, a na 200 mg od 2. ciklusa nadalje ako se podnosi doza od 100 mg. b Bolesnicima koji nakon 4 ciklusa postignu najmanje parcijalni odgovor, može se dati do 6 ciklusa
Vc=VELCADE; M=melphalan, P=prednisone
period odmora
VCR (1.5 mg/m2/day, IV): days 1, 29
VCR (1,5 mg/m²/dan, i.v.): dani 1, 29
VCR (1.5 mg/m2/day, IV): days 1, 8 and 15
VCR (1,5 mg/m²/dan, i.v.): dani 1, 8 i 15
VCR (1.5 mg/m2/day, IV): days 1, 8, and 15
VCR (1,5 mg/m²/dan, i.v.): dani 1, 8, i 15
VCR 1.3 g/m2 i.v., day 1;
VCR 1,3 g/m2 i.v., dan 1;
VCR 2 mg i.v. monthly for 13 months;
VCR 2 mg i.v. mjesečno tijekom 13 mjeseci;
VcR-CAP
VcR-CAP (N = 240)
VcR-CAP=VELCADE, rituximab, cyclophosphamide, doxorubicin, and prednisone; R-CHOP= rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone; PN=peripheral neuropathy
VcR-CAP = VELCADE, rituksimab, ciklofosfamid, doksorubicin i prednizon; R-CHOP = rituksimab, ciklofosfamid, doksorubicin, vinkristin i prednizon; PN = periferna neuropatija
Vd Arm (N = 465)
Vd skupina (N = 465)